- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02504762
HYbrid CoronAry Revascularization in DiabeticS (HYCARDS)
HYbrid CoronAry Revascularization in DiabeticS: A Randomized Controlled Trial (Pilot)
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Globally, diabetes mellitus has become a major threat to human health. An increase in the prevalence of diabetes has been observed, which in part can be attributed to the aging of the population, as well as to an increase in the rate of obesity and sedentary lifestyle in Canada and the United States.1 Diabetes mellitus is an emerging epidemic with an estimate, currently, of almost 18 million confirmed cases and another 20 million patients with impaired glucose tolerance at risk to diabetes, in the United States alone.2,3
Diabetes mellitus, either Type-I or Type-II, is a very strong risk factor for the development of coronary artery disease (CAD) and stroke. Eighty percent of all deaths among diabetic patients are due to atherosclerosis, compared to about 30% among non-diabetic patients.2 A large NIH cohort study, the First National Health and Nutrition Examination Survey, revealed that heart disease mortality in the general population is declining at a much greater rate than in diabetic patients. In fact, diabetic women suffered an increase in heart disease mortality over the same time period.4,5 Furthermore, despite recent reductions in cardiovascular events amongst adults with diabetes, the absolute risk of cardiovascular events remains 2- fold greater than amongst non-diabetic individuals.6
There are various methods by which we can treat multivessel CAD in diabetic patients. Although conventional bypass (cCABG) is more beneficial than percutaneous coronary intervention (PCI) with drug eluting stents (DES) for myocardial revascularization in diabetics with multivessel CAD, diabetics are also the patients who experience the most complications, infections, and highest costs with cCABG through a sternotomy. Recently, we developed and diffused MICS CABG, which can be combined with PCI/DES to vessels other than the one at the front of the heart in order to constitute hybrid coronary revascularization (HCR). The safety and efficacy of MICS CABG was recently validated in a multicentre study from our research team, with 100% patency of the left internal thoracic artery (LITA)-LAD axis on angiography7. Potential advantages of an HCR approach in diabetics include the avoidance of a sternotomy and the potential for earlier recovery, less bleeding and transfusions, fewer infections, decreased costs, increased patient acceptance, while potentially maintaining the benefits of cCABG due to the LITA-LAD axis in a diabetic population.
Despite HCR's theoretical advantages as outlined above, it is a novel innovative approach that has not been studied in a randomized setting, nor in the context of diabetic patients. Its rationale and main research question stem from MICS CABG work by the principal investigator, as well as his recent, collaborative Lancet meta-analysis which revealed that diabetic patients with multivessel coronary disease (CAD) have better much survival with bypass surgery than with stents8. However, diabetics are also the patients who experience the most complications and infections from cCABG with incision of the breastbone. The investigators main hypothesis is therefore that a HCR strategy in diabetics with multivessel CAD will combine the benefits of bypass surgery on the artery at the front of the heart (the LAD), nearly eliminate the risk of complications and wound infection, and allow for faster recovery and improved quality of life when compared to cCABG. Other blockages would be treated with a PCI/DES to reduce the invasiveness of the procedure.
Overall, the investigators believe that the equipoise as to whether HCR is better than cCABG in diabetic patients with multivessel CAD constitutes the next important question in the diabetes/CAD field. The investigators propose to evaluate the feasibility of a definitive trial examining this question by conducting the present pilot trial.
Upon study approval, the time frame will be one year of recruitment, followed by 1 year of follow-up. Since this is a pilot trial, the investigators are assessing the feasibility of conducting this trial on diabetic patients with multivessel coronary artery disease. Should this trial be feasible, the investigators will extend the study to a full-scale study. At that time, an application will be submitted to conduct the study.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1Y 4W7
- Division of Cardiac Surgery, University of Ottawa Heart Institute
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or Female, aged 18 years or older;
- Diabetes Mellitus (Type 1 or Type 2) undergoing treatment;
- Multivessel disease involving the LAD + at least one other coronary territory (stenosis ≥ 70% in a 1.5 mm artery) in a patient referred for cCABG;
- Angiographic lesion characteristics amenable to both PCI/DES and MICS CABG;
- Indication for revascularization based upon objective ischemia.
Exclusion Criteria:
- Severe congestive heart failure (class III or IV NYHA) at enrollment;
- Left ventricular ejection fraction less than 20%;
- Prior CABG surgery;
- Prior heart valve surgery;
- Prior PCI within the previous 6 months;
- Previous tuberculosis or trauma to the chest that may have caused adhesions or LITA damage;
- Previous stroke within 6 months or patients with stroke at more than 6 months with significant residual neurologic involvement, as reflected by a Rankin Score > 1;
- Prior history of significant bleeding that might be expected to recur with MICS CABG or PCI/DES related anticoagulation;
- STEMI or Q-wave MI within 72 hours prior to enrollment;
- Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting);
- Contraindication to either cCABG, MICS CABG, or PCI/DES because of a coexisting clinical condition;
- Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis;
- Intolerance or contraindication to aspirin or both clopidogrel and ticagrelor;
- Dementia with a Mini Mental Status Examination (MMSE) score of < 20;
- Extra-cardiac illness that is expected to limit survival to less than 5 years;
- Suspected pregnancy. A pregnancy test (urine or serum) will be administered to all women not clearly menopausal;
- Concurrent enrollment in another clinical trial;
- Geographic inaccessibility for the follow-up visits required by protocol.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Treatment: HCR
Participants will be randomized into the treatment or control group.
In the treatment group, participants will be treated with PCI and MICS CABG.
In the control group, participants will be treated with conventional CABG for their multivessel CAD.
|
Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention.
This study is a surgical intervention, which does not involve a drug or device intervention.
|
Active Comparator: Control: Conventional CABG
Participants will be randomized into the treatment or control group.
In the treatment group, participants will be treated with PCI and MICS CABG.
In the control group, participants will be treated with conventional CABG for their multivessel CAD.
|
Conventional CABG.
This study is a surgical intervention, which does not involve a drug or device intervention.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Assessing conventional CABG vs HCR in diabetic patients with multivessel CAD
Aikaikkuna: Up to 24 months
|
To determine whether a hybrid strategy to treat multivessel CAD in diabetics is more or less effective than conventional CABG
|
Up to 24 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
≥ 95% participant adherence
Aikaikkuna: Up to 24 months
|
Adherence defined as ≥ 95% of the prescribed randomized revascularization index
|
Up to 24 months
|
Minimizing procedural crossovers
Aikaikkuna: Up to 24 months
|
Minimization of procedural crossovers in regards to patients crossing from one modality to the other, prior, during, or early failure of the planned, assigned index procedure
|
Up to 24 months
|
≥ 95% follow-up rate
Aikaikkuna: Up to 24 months
|
One year follow-up rates will be ≥ 95%
|
Up to 24 months
|
Number of patients we can enroll in 1 year
Aikaikkuna: Up to 24 months
|
How many eligible and consenting patients can be successfully enrolled in 1 year, and followed-up for 1 year
|
Up to 24 months
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Marc Ruel, MD. MPH, Ottawa Heart Institute Research Corporation
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998 Apr;21(4):518-24. doi: 10.2337/diacare.21.4.518.
- Ruel M, Shariff MA, Lapierre H, Goyal N, Dennie C, Sadel SM, Sohmer B, McGinn JT Jr. Results of the Minimally Invasive Coronary Artery Bypass Grafting Angiographic Patency Study. J Thorac Cardiovasc Surg. 2014 Jan;147(1):203-8. doi: 10.1016/j.jtcvs.2013.09.016. Epub 2013 Oct 30.
- Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ. Trends in cardiovascular complications of diabetes. JAMA. 2004 Nov 24;292(20):2495-9. doi: 10.1001/jama.292.20.2495.
- Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004 Nov 19;53(45):1066-8.
- Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999 Sep 7;100(10):1134-46. doi: 10.1161/01.cir.100.10.1134. No abstract available. Erratum In: Circulation 2000 Apr 4;101(13):1629-31.
- Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999 Apr 14;281(14):1291-7. doi: 10.1001/jama.281.14.1291.
- Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC. Diabetes mellitus and its vascular complications in Japanese migrants on the Island of Hawaii. Diabetes Care. 1979 Mar-Apr;2(2):161-70. doi: 10.2337/diacare.2.2.161.
- Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, Sud S, Gupta M, Singh S, Gupta N, Cheema AN, Leiter LA, Fedak PW, Teoh H, Latter DA, Fuster V, Friedrich JO. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2013 Dec;1(4):317-28. doi: 10.1016/S2213-8587(13)70089-5. Epub 2013 Sep 13.
- Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20;367(25):2375-84. doi: 10.1056/NEJMoa1211585. Epub 2012 Nov 4.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 20150338
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.ValmisDiabetes mellitus, tyyppi 1 | Tyypin 1 diabetes | Diabetes tyyppi 1 | Tyypin 1 diabetes mellitus | Autoimmuuni Diabetes | Diabetes mellitus, insuliinista riippuvainen | Nuorten diabetes | Diabetes, Autoimmuuni | Insuliiniriippuvainen diabetes mellitus 1 | Diabetes mellitus, insuliinista riippuvainen, 1 | Diabetes... ja muut ehdotYhdysvallat
-
Guang NingRekrytointiTyypin 2 diabetes mellitus | Tyypin 1 diabetes mellitus | Monogeneettinen diabetes | Pankreatogeeninen diabetes | Huumeiden aiheuttama diabetes mellitus | Muut diabetes mellituksen muodotKiina
-
Northern Care Alliance NHS Foundation TrustBrighter ABValmisDiabetes tyyppi 1 | Diabetes tyyppi 2Yhdistynyt kuningaskunta
-
VeraLight, Inc.InLight SolutionsTuntematonRaskausajan diabetes | Insuliiniriippuvainen diabetes | Insuliinista riippumaton diabetesYhdysvallat
-
Haukeland University HospitalTuntematonInsuliiniriippuvainen diabetes mellitus | Nuorten aikuisten diabetes, tyyppi 3 | Nuorten aikuisten diabetes, tyyppi 1 | Lapsuuden diabetes mellitusNorja
-
Steno Diabetes Center CopenhagenUniversity of CopenhagenValmisTyypin 2 diabetes | Nuorten aikuisten diabetes, tyyppi 3Tanska
-
Imperial College LondonTuntematonDiabetes | Tyypin 1 diabetes | Tyypin 2 diabetes | Nuorten aikuisten diabetesYhdistynyt kuningaskunta
-
Bruce A. BuckinghamValmisTyypin 1 diabetes mellitus | Autoimmuuni Diabetes | Nuorten diabetes | Diabetes, mellitus, tyyppi 1Yhdysvallat
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRekrytointiDiabeteksen komplikaatiot | Tyypin 2 diabetes | Nuorten aikuisten diabetes (MODY)Taiwan
-
Zhejiang Provincial People's HospitalEi vielä rekrytointiaTyypin 2 diabetes | tyypin 1 diabetesKiina
Kliiniset tutkimukset Treatment
-
University of California, San FranciscoUniversity of California, DavisValmis
-
The Cleveland ClinicTwin HealthAktiivinen, ei rekrytointi
-
RANDUniversity of California, Los Angeles; Bill and Melinda Gates Foundation; Pathfinder...ValmisPerhesuunnittelupalvelutYhdysvallat
-
Gala Therapeutics, Inc.Valmis
-
VA Office of Research and DevelopmentValmis
-
Karolinska InstitutetHanoi Medical UniversityTuntematonIhmisen immuunikatovirus (HIV)Vietnam
-
FA CorporationUniversity of Texas Southwestern Medical CenterIlmoittautuminen kutsusta
-
Advanced Bariatric TechnologyNAMSAEi vielä rekrytointiaYlipaino ja lihavuus
-
Stanford UniversityValmisKehitysvamma | Puheen viive | KielihäiriöYhdysvallat
-
National Jewish HealthNovartis Pharmaceuticals; Akili Interactive Labs, Inc.TuntematonLupus erythematosus, systeeminenYhdysvallat